All In Biotech

Drug Trial Radar · NCT02918019

A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study to Assess the Efficacy and Safety of MSTT1041A in Patients With Uncontrolled Severe Asthma

Last checked: Nov 19, 2026Latest source record: Dec 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 517 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

517

Actual

Start

Sep 20, 2016

Primary completion

Apr 5, 2019

Study completion Jul 26, 2019

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Sep 28, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase IIb, randomized, placebo-controlled, double-blind, multicenter, multi-arm study which will evaluate efficacy, safety, and pharmacokinetic of MSTT1041A compared with placebo as add-on therapy in participants with severe, uncontrolled asthma who are receiving medium- or high-dose inhaled corticosteroid (ICS) therapy and at least one of the following additional controller medications: long-acting beta-agonists (LABA), leukotriene modifier (LTM), long-acting muscarinic antagonist (LAMA), or long-acting theophylline preparation. The total duration of this study for each participant is approximately 70 weeks including screening, run-in, treatment, and follow-up.

Conditions

  • Asthma

Interventions

  • MSTT1041ADrug

    MSTT1041A will be administered as subcutaneous injections.

  • PlaceboDrug

    Placebo matched with MSTT1041A.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction in Rate of Asthma ExacerbationsTime frame: Baseline to Week 54

Locations

138 sites in 15 countries. Site status is shown where the registry gives one.

  • Alabama Allergy & Asthma

    Birmingham, Alabama

  • Del Sol Research Management

    Tucson, Arizona

  • Kern Allergy Med Clinic, Inc.

    Bakersfield, California

  • Allergy & Asthma Care Center of Southern California

    Long Beach, California

  • CA Allergy & Asthma Med Grp; Medical Group, Inc.

    Los Angeles, California

  • Jonathan Corren MD, Inc.

    Los Angeles, California

  • Office of Robert N Wolfe MD

    Los Angeles, California

  • Advances in Medicine

    Rancho Mirage, California

  • Allergy & Asthma Consultants

    Redwood City, California

  • Bensch Research Associates

    Stockton, California

  • Allergy and Asthma Clinical Research, Inc.

    Walnut Creek, California

  • IMMUNOe Research Centers

    Centennial, Colorado

  • Asthma & Allergy; Associates, P.C.

    Colorado Springs, Colorado

  • Western States Clinical Research, Inc

    Wheat Ridge, Colorado

  • Yale University School Of Medicine

    New Haven, Connecticut

  • Emerald Coast Research Associates

    Panama City, Florida

  • Florida Premier Research Institute

    Winter Park, Florida

  • Atlanta Allergy & Asth Clin PC

    Stockbridge, Georgia

  • Asthma & Allergy of Idaho

    Twin Falls, Idaho

  • Asthma, Allergy & Sinus Center

    Baltimore, Maryland

  • Chesapeake Clinical Research Inc - CRN

    Baltimore, Maryland

  • Genesis Clinical Research & Consulting, LLC

    Fall River, Massachusetts

  • Infinity Medical Research Inc

    North Dartmouth, Massachusetts

  • Midwest Clinical Research LLC

    St Louis, Missouri

  • The Allergy and Asthma Center

    Bellevue, Nebraska

  • Montefiore Medical Center

    The Bronx, New York

  • American Health Research Inc.

    Charlotte, North Carolina

  • Allergy & Respiratory Center

    Canton, Ohio

  • Integrity People Services Research Company

    Oklahoma City, Oklahoma

  • Vital Prospects Clin Res Pc

    Tulsa, Oklahoma

  • Temple University Hospital

    Philadelphia, Pennsylvania

  • Asthma & Allergy Physicians of Rhode Island Clinical Research Institute (AAPRI CRI)

    Warwick, Rhode Island

  • Spartanburg Medical Research

    Spartanburg, South Carolina

  • Clinical Research Solutions PC

    Knoxville, Tennessee

  • Meharry Medical College; Clinical Trials Office

    Nashville, Tennessee

  • TTS Research

    Boerne, Texas

  • Elliot J. Ginchansky, MD, PA

    Dallas, Texas

  • Pioneer Research Solutions

    Houston, Texas

  • Metroplex Pulmonology & Sleep Center

    McKinney, Texas

  • Allergy & Asthma Research Center

    San Antonio, Texas

Showing 40 of 138 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.